Romans 12:19
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
look at my posting history then stfu
..though you and I are not in the position to make that claim now.. are we? lets just keep honest ok? I want honest success.
SWX: RLF
0.50 CHF -0.028 (5.30%)
Sep 8, 1:54 PM
Not everyone here is a "money hungry investors so desperate for news and attention" ..the story landed on us and it's apart of the whole along with other aspects all around the World.. and I am far more motivated by his three daughters having their father alive and well than making money when it concerns him. ..maybe you're projecting your own ways of thought on others ?
"Aviptadill has eradicated Covid-19" ..not sure we can make that claim.. but the way it's helped a number in the past things are looking good..
Sepsis, every time I hear about Sepsis I think about Tony Soprano.. it's not always the gunshot but the sepsis that follows that is the battle..
.. sounds like his body is kicking in and he has a shot..
$RLFTF Can have (and probably will have) a 2-6 fold share price jump before a reverse split is even considered if at all IMO
Covid 19 Long Term Effects: "Heart & Lungs" So You Survive Covid 19; How Long Do You Survive After Recovery If Your Heart And Lungs Have Been Severely Damaged...Mayo Clinic Aug18.2020 Heart & Lung Damage:
https://www.mayoclinic.org/diseases-conditions/coronavirus/in-depth/coronavirus-long-term-effects/art-20490351
Copy from beatcovid post RVVTF board
SWX: RLF
0.52 CHF +0.020 (3.97%)
Sep 7, 3:33 PM
..steady day so far..
OT: A few times I noticed a reaction within me jump up towards posts with Political and Religious content outside of The President mentioned therapeutics.. (that IMO can be on topic..)
But when the posts are charged with strong opinion/emotion.. man that's just drama time.. and so I didn't react because there will be 50% of the people here who won't see things as I do.. and things will get out of control.
There are other boards on iHUB to get into these topics below..
Have at it ;)
https://investorshub.advfn.com/Simply-Politics-GOV-444/
https://investorshub.advfn.com/Just-Politics-11305/
https://investorshub.advfn.com/Bible-Bible-424/
https://investorshub.advfn.com/ETERNITY-8534/
$GRLB GL Brands On The Net..
Company website https://glbrands.com/
---
Instagram https://www.instagram.com/glbrandsinc/
https://www.instagram.com/greenlotushemp/
https://www.instagram.com/iriehemp/
---
GL Brands on YOUTUBE
SWX: RLF
0.53 CHF +0.024 (4.76%)
Sep 7, 9:59 AM
Google SWX: RLF (put in fav. bar for future quotes)
$RLFTF Interesting DD by John - on yho
Here are a few things that were happening in the background.
1. GEM gave more money to RLFTF at the end of August.
2. NeuroRx updated the endpoint information in the clinical trials website at the end of August. They deleted some sites that probably have not started recruiting. They did not change completion dates and sample size.
3. Relief hired new CMO on Sep 4th.
4. They remain silence about the trial data.
Why did GEM give RLFTF 32 million at the end of August?
Why did NeuroRx updated the trial information at the end of August?
The interim data must have been very positive and GEM was updated. If negative, do you think GEM will give 32 million to them?
My estimation shows that the interim has been done in/before the week of August 24. This timeline is consistent with what were happening.
If the interim was a blowout, who will they first share with? FDA! That may be why they were so silent, as exciting things are brewing and they do not want anyone to mess it up. Just connect the dots.
Big news is coming.
..you're basically right..
..lets not forget Malpractice Insurance high maintenance wives and the pool boy $$$$$$ ;)
Don't need to read the report to see it's positive.. IMO
---
Relief Therapeutics share: Will this be the next price explosion?
By Christina Rothstein -6 September 2020
Just a few weeks ago, most investors had very little to do with Relief Therapeutics. However, the Swiss company made a name for itself overnight with the hopeful Aviptadil, which is considered extremely promising in the treatment of Corona patients. The prices have exploded and are still at a very high level, despite the interim correction. The latest reports offer hope that the prices could soon target higher spheres again. On Friday, we were already heading in the right direction.
Should investors sell immediately? Or is it worth getting started at Relief Therapeutics?
Support for research
As Relief Therapeutics announced over the weekend, the company is now receiving support in the form of a new CEO. Gilles Della Corte joins the company, which has 30 years of experience in the biopharmaceutical industry alone. Among other things, he will be responsible for the clinical development of Aviptadil in Europe and will work with NeuroRx to work towards approval both in local areas and in the USA. /// This gives the impression that research and development is now being properly pressed on the gas. ///
Relief Therapeutics shares soar
On the stock exchange, the news was well received. Buyers sent Relief Therapeutics shares up more than 3 percent on Friday, successfully defending the 0.50 CHF mark at the close of the week. The paper takes further upside potential into the new week. The long-term outcome will depend to a large extent on the further development around Aviptadil. Speed is a factor that should not be underestimated. After all, the expected sales are all the higher as long as no approved vaccine is available and the number of infections continues to increase worldwide.
Buy, Hold or Sell – Your Relief Therapeutics Analysis of 06.09. provides the answer:
How will Relief Therapeutics develop now? Is your money safe in this stock? The answers to these questions and why you need to act now can be found in the latest Relief Therapeutics Stock analysis.
Relief Therapeutics: Buy or sell? (read more here)
https://www.finanztrends.info/relief-therapeutics-aktie-bringt-das-die-naechste-kursexplosion/
$RLFTF We're a couple weeks away from a whole new perception IMO
1970 Pontiac GTO .. NICE!! had a few old Firebirds myself..
.. I only ask 'cause it's a German Shepherd ;)
..do you drive an American or German car/truck ?
Update: 9/6 AM
X-rays were taken overnight and showing improvement in passages of upper but worsening in passages of lower. APRV mode on the vent and this morning it is set at 40%. The ECMO is now at 60%. Blood pressure did well overnight but dropped some this morning so meds were administered to help bring it back where it needs to be. No blood was needed overnight. The daily fluid balance for the last 24 hours was -2629 mL. The nurse said swelling has decreased and he’s starting to look like himself again.
N/P.. it's been a common topic.. my nephew is into that and bitcoin.. I have no idea.. but I figured many of them will have portfolios on the side to buy..
Update: 9/5 AM
X-rays this morning showed small improvement in left but slightly worse on right. The vent is still APRV and set currently at 40%. ECMO this morning is set at 80%. Blood pressure is still a little low but more steady today. He’s currently getting a unit of blood. All other labs are within normal range. Daily fluid balance was -1 L for the last 24 hours.
I don't believe Robinhood trades this... don't really need 'em IMO
I think the Frias brothers are from there.. ? ..lets hope the Share price gets as BIG as everything else in Texas..
$GRLB GL Brands On The Net..
Company website https://glbrands.com/
---
Instagram https://www.instagram.com/glbrandsinc/
https://www.instagram.com/greenlotushemp/
https://www.instagram.com/iriehemp/
---
GL Brands on YOUTUBE
Update: 9/4 PM
No additional x-rays this afternoon. The vent is still in APRV mode and set at 50%. ECMO is currently set at 85%. Blood pressure is being a little stubborn (low) so he’s getting some meds to help. They are still working on excess fluid removal and today’s balance is negative overall again so far.
Coronavirus deaths in US could top 400K by end of year, updated model predicts https://fxn.ws/3jPLZlE #FoxNews
..another pointed on another board the lung injury Covid-19 causes.. RLF-100 is important.
$RLFTF Phase IIb/III studies in Acute Respiratory Distress Syndrome induced by COVID-19:
Two phase IIb/III clinical studies to document Aviptadil efficacy in patients with severe or moderate COVID-19 induced ARDS are on-going. These trials are done in partnering with NeuroRx, a US based company
( http://neurorxpharma.com/).
Aviptadil for COVID-19 Associated Acute Respiratory Distress (COVID-AIV)
A multicenter, placebo-controlled, quadruple masking (Participant, Care Provider, Investigator, Outcomes Assessor), randomized interventional clinical trial.
Patients with COVID-19 induced Acute Respiratory Distress Syndrome who are admitted for intensive care including endotracheal intubation and mechanical ventilation will be treated with Aviptadil, plus maximal intensive care vs. placebo, plus maximal intensive care. Patients will be randomized to intravenous Aviptadil will receive escalating doses from 50 -150 pmol/kg/hr over 12 hours. This trial has been expanded to include patients receiving high flow oxygen and noninvasive ventilation (CPAP), in addition to those on ventilators. The primary endpoint will be mortality at 5 days with follow-up through 30 days.
Estimated Study Completion Date: September 2020
Further details on ClinicalTrials.gov, identifier: NCT04311697.
Aviptadil for the Treatment of Non-Acute Lung Injury in COVID-19 (AVINALI):
A multicenter, placebo-controlled, quadruple masking (Participant, Care Provider, Investigator, Outcomes Assessor), randomized interventional clinical trial.
Patients with COVID-19 induced non-Acute Lung Injury who have demonstrated reduction in blood oxygenation, dyspnea, and exercise intolerance but do not require endotracheal intubation and mechanical ventilation will be treated with Aviptadil plus Standard of Care vs. placebo, plus Standard of Care. Patients will be randomized to inhaled Aviptadil, 100 µg/inhalation, 3x daily vs. placebo 3x daily. The primary outcome will be progression to ARDS over 28 days. Estimated Study Completion Date: October 1, 2020
Further details on ClinicalTrials.gov, identifier NCT04360096
https://relieftherapeutics.com/clinical-trials-2/
No general vaccination before mid-2021, according to WHO
September 4,2020
Geneva | The World Health Organization (WHO) said on Friday it would not expect a widespread vaccination against COVID-19 until mid-2021, as preparations for the distribution of a vaccine accelerate in the United States.
“As you know, a considerable number of applicants have now entered phase 3 of the trials. We know of at least 6 to 9 who have already come a long way in terms of research, ”WHO spokesperson Margaret Harris told a press briefing in Geneva.
“But in terms of a realistic schedule, we really don’t expect to see widespread vaccination until the middle of next year,” she added.
The spokesperson explained that sentence 3 of clinical trials – that is, the stage of massive testing on volunteers – is taking time, as scientists need to verify whether the vaccine is effective and safe.
Several pharmaceutical company executives for their part pledged Thursday to “cut corners” and to respect “safety” standards in the race for the vaccine against COVID-19, despite sometimes insistent calls to prefer it. the rapidity.
But “the good news is that manufacturers are already betting on which vaccine is likely to be, and are already thinking about how they can increase vaccine production once we know which one will be used.” Ms. Harris pointed out.
Competition rages on to develop a vaccine against COVID-19.
In the United States, the most bereaved country in the world, the Centers for Disease Prevention and Control (CDC) have “urgently” called on states to do what is necessary so that the distribution centers for a future vaccine can be ” fully operational by November 1, 2020 ”, just before the presidential election.
At the end of August, US President Donald Trump had also promised a vaccine “this year” against COVID-19.
In Geneva, Soumya Swaminathan, chief scientist at the WHO, told reporters this week that the organization has worked with experts from around the world, including the United States Medicines Agency (FDA) and the European Agency. drugs (EMA), to “propose criteria” for the safety and efficacy of future vaccines.
“We would like to see a vaccine with at least 50% efficacy, preferably better,” she said.
https://balthazarkorab.com/2020/09/04/covid19-no-general-vaccination-before-mid-2021-according-to-who/
President talking about Therapeutics 50-85% better..
https://www.facebook.com/watch/?v=2770551909830245&extid=X6fWi1iEorMOYjQH
UPDATE.. Here it is
https://www.facebook.com/watch/?v=2770551909830245&extid=X6fWi1iEorMOYjQH
?? J-Belfort ??
Friday, September 4, 2020 12:46:44 PM
Is there any link for this or transcript or anything?
..if you're talking about my post below it was on fox news.. earlier and paraphrased.. maybe the network website has a replay..
yeah he paused and said we have ones from 50 to 85% now.. so.. He ended with talking about it again at 5:00.. He seems more willing to drop names.. on Vaccines.. but no names on therapeutics.. the 85% therapeutic made me think Relief
..they're letting his body take on some more of the work.. good sign..
..yeah he paused and said we have ones from 50 to 85% now.. so.. He ended with talking about it again at 5:00.. He seems more willing to drop names.. on Vaccines.. but no names on therapeutics.. the 85% therapeutic made me think Relief
$RLFTF Relief Therapeutics: Gilles Della Corte, new medical director FRIDAY, 04.09.2020
The biotech company Relief Therapeutics has appointed Gilles Della Corte as medical director with immediate effect, the Geneva-based company announced on Friday.
Dr. Della Corte, a cardiologist, has more than 30 years of experience in the biotechnology sector.
Relief Therapeutics announced on Friday the appointment of Gilles Della Corte, M.D., as medical director, with immediate effect.
Dr. Della Corte, a cardiologist, has more than 30 years of experience in the biotechnology sector, including at Merck Serono, where he was responsible for development, from proof of concept to project lifecycle management in several pathological areas, including cardiology, rheumatology, oncology and endocrinology.
Earlier in his career, he also held positions of (cont'd)
https://www.agefi.com/home/entreprises/detail/edition/online/article/la-societe-biotechnologique-relief-therapeutics-a-nomme-avec-effet-immediat-gilles-della-corte-au-poste-de-directeur-medical-a-annonce-vendredi-lentreprise-genevoise-498663.html
SWX: RLF
0.52 CHF +0.035 (7.16%)
Sep 4, 1:49 PM
Fauci says coronavirus vaccine won't be distributed unless it's based on 'hard data' http://a.msn.com/05/en-us/BB18GB3D?ocid=st
$RLFTF Relief Appoints Gilles Della Corte, M.D. as Chief Medical Officer Geneva, Switzerland, September 04, 2020
– RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) (“Relief” or the “Company“), a biopharmaceutical company with its lead compound aviptadil in advanced clinical development to treat severe COVID-19 patients, today announced the appointment of Gilles Della Corte, M.D., as Chief Medical Officer, effective immediately.
https://relieftherapeutics.com/relief-appoints-gilles-della-corte-m-d-as-chief-medical-officer/
$RLFTF Relief Appoints Gilles Della Corte, M.D. as Chief Medical Officer Geneva, Switzerland, September 04, 2020
– RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) (“Relief” or the “Company“), a biopharmaceutical company with its lead compound aviptadil in advanced clinical development to treat severe COVID-19 patients, today announced the appointment of Gilles Della Corte, M.D., as Chief Medical Officer, effective immediately.
https://relieftherapeutics.com/relief-appoints-gilles-della-corte-m-d-as-chief-medical-officer/
Dr marty makary john hopkins just now! "THERAPEUTICS WILL BEAT ALL"------------even vaccines! fox bus channel----folks, he said it CLEARLY. Therapeutics will be the winners
from ya--hoo mrdec123
..many I'm reading refuse to get the shot and some say 30% effective.. not sure the possible side effects is worth the risk.. that and we deal with them while they're in the hospital.. so I didn't post the link earlier 'cause it won't effect us much IMO ..but glad you posted it.. we'll see how people feel about the shot ;)
Global Emerging Markets (“GEM”) is a $3.4 billion alternative investment group that manages a diverse set of investment vehicles focused on emerging markets across the world. GEM’s investment vehicles provide the group and its investors with a diversified portfolio of asset classes that span the global private investing spectrum.
https://www.gemny.com/
------
GEM Global Yield Fund LLC
Organization
GEM Global Yield Fund LLC operates as a private equity firm. The Company focuses on management buy-outs, acquisitions, mergers, recapitalizations, restructuring, and other corporate situations. GEM Global Yield Fund serves clients worldwide.
Founded: Nov 13, 2012
Headquarters: New York, NY
https://www.bloomberg.com/profile/company/1646701D:US
SWX: RLF 0.52 CHF -0.0080 (1.53%)